Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Ma Xing Shi Gan Decoction is a traditional Chinese medicine (TCM) polyherbal formulation being evaluated for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). This specific modification, studied by investigator Cuiling Feng, is based on the classic Ma Xing Shi Gan Decoction—originally consisting of *Ephedra sinica*, *Prunus armeniaca*, *Gypsum fibrosum*, and *Glycyrrhiza uralensis*—and is tailored to address the 'Lung-Large Intestine Mutual Interior-Exterior Relationship' theory. The formula is intended to clear lung heat, resolve phlegm, and relieve dyspnea by modulating systemic and local inflammation. In clinical trials, it is administered as an oral decoction in combination with standard Western medical care (such as bronchodilators and antibiotics), with the primary goal of reducing hospital stay duration and improving clinical symptoms like cough, phlegm, and breathlessness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Ma Xing Shi Gan Decoction.